ClinicalTrials.gg
TerminatedNCT07170254Updated Sep 4, 2026

A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL

An Early Phase 1 interventional study of BD114VLP, or BD114 in High-grade Squamous Intraepithelial Lesions (HSIL), sponsored by Shanghai BDgene Co., Ltd.. Terminated at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Shanghai BDgene Co., Ltd. · Early Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Adjustment Per devolpment strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Squamous Intraepithelial Lesions with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Squamous Intraepithelial Lesions · China.

Enrollment
14th of 14
2 · median 153
Started
2025
with 2 others
Phase 1
3 of 26
1 open now
Registered
22nd of 26
by date
Lead sponsor
1 of 26
Shanghai BDgene Co., Ltd.

Among the 26 studies in Squamous Intraepithelial Lesions with a site in China, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 1, and was the 22nd registered.

Squamous Intraepithelial Lesions

104 studies on the registry are indexed under Squamous Intraepithelial Lesions; 36 are open to participants now.

Browse Squamous Intraepithelial Lesions studies →

Open to participants now

17 of the 26 studies in Squamous Intraepithelial Lesions with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Squamous Intraepithelial Lesions studies recruiting now, 11 (48%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Squamous Intraepithelial Lesions with a site in China, or all of them as a file.
02

Study summary

This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 infection.

Read the detailed description

This study is an open-label, two-arm, balanced-group, single-dose, non-randomized exploration clinical study. A total of 6 patients with HPV-16 Related HSIL of the Cervix will be enrolled and divided into two arms. Participant in Arm 1(n=1) receive topically low-dose of BD114 with intraepithelial injection of lesions, and participants in Arm 2 (n=5) receive high-dose of BD114 with intraepithelial injection of lesions. The total follow-up duration for each participant is 40 weeks (including screening stage). The treatment-emergent adverse events (TEAEs) for safe evaluation, components detection of the BD114 for pharmacokinetics (PK) assessment, histologically lesion regression or clearness and virologically HPV-16 clearness for efficacy evaluation are conducted and explored during follow-up visits.

03

Conditions studied

  • High-grade Squamous Intraepithelial Lesions (HSIL)

Keywords

  • High-grade squamous intraepithelial lesions
  • HPV-16 infection
  • Gene Editing Therapy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, aged 18 to 50 years, without childbearing demand;
  2. Confirmed histopathological evidence of cervical HSIL (CIN3) at the screening period or within 1 month prior to screening;
  3. Confirmed cervical HPV-16 positive by HPV test during the screening period or within 1 month prior to screening, without other high-risk HPV types detected;
  4. Complete visibility of both the squamocolumnar junction (SCJ Types 1/2) and the upper margin of acetate-white epithelium or suspected HSIL lesions under colposcopy examine during the screening period or within 1 month prior to screening;
  5. No evidence of precancerous lesions or by endocervical curettage (ECC) ;
  6. The sampling of cervical lesions are performed;
  7. Visible residual cervical lesions after screening biopsy;
  8. Willing to maintain abstinence or use a highly effective method (oral contraceptives, injections, implants, or barrier methods) for women of (WOCBP) from enrollment until Week 36, or her partner undergone surgical sterilization (e.g., vasectomy);
  9. Good compliance to protocol-specified procedure in study duration assessed by investigator;
  10. Voluntarily participating in the study and willing to provided signed .

Exclusion criteria

Exclusion Criteria:

  1. Positive detection of antibodies or viral test of (HIV), or virus (HBV), or virus (HCV), or Treponema pallidum (TP) at screening;
  2. Confirmed histopathologically epithelial carcinoma, glandular carcinoma or precancerous lesions in the endometrium at screening;
  3. Confirmed histopathologically or macroscopically high-grade intraepithelial neoplasia or invasive carcinoma in the vulva, vagina or anus at screening;
  4. HSIL with partial location in cervical canal and incomplete colposcopic visualization ;
  5. Undergone the treatment for cervical HSIL within 4 weeks prior to screening;
  6. Vaccination history of any therapeutic HPV vaccine;
  7. Family history of , or a history/current presence of any malignant tumor;
  8. Severe uncontrolled diseases of major organs, including but not limited to: acute myocardial infarction, stroke, liver cirrhosis, severe kidney disease, diabetes mellitus, (COPD), hematologic disorders, psychiatric disorders, etc;
  9. Pregnant (a positive urine or serum pregnancy test) or lactating women;
  10. Participating in another drug or device clinical trial at screening, or participated in one within 3 months prior to screening;
  11. The history of any form of gene and/or cell therapy;
  12. Drug abuse or alcohol addiction no compliance to protocol-specific procedure;
  13. Any other condition unsuitable for participating this study judged by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    BD114 Low-dose group

    BD114 Low-dose group: Low-dose (n=1) * Small lesions (≤5 mm\^2): BD114 injection, 0.2 mL * Large lesions (\>5 mm\^2): BD114 injection 0.4 mL

    Genetic: BD114VLP, or BD114

  • Experimental
    BD114 High-dose group

    BD114 High-dose group: High-dose (n=5) * Small lesions (≤5 mm\^2): BD114 injection, 0.3 mL * Large lesions (\>5 mm\^2): BD114 injection 0.6 mL

    Genetic: BD114VLP, or BD114

Interventions

  • GeneticBD114VLP, or BD114

    CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression. A single dosing BD114 injection by topical intraepithelial injection of HSIL lesion.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs) and serious adverse events (SAEs)

    All AEs and SAEs occurring during the study period (from informed consent signing to Week 36 post-BD114 intervention) were recorded and assessed according to the NCI-CTCAE v5.0 grading system, including their classification by System Organ Class (SOC), severity grade, number of affected Participants, and incidence rates. Gynecological AEs (beyond NCI-CTCAE v5.0 specifications) shall be evaluated by investigators for classification and severity grading according to current clinical guidelines/expert consensus.

    Time frame: ~36 weeks

  2. Percentage of Participants with No Histologic Evidence of HSIL

    Cervical tissue biopsies obtained at Week 24 and Week 36 undergo histopathological evaluation, and judge the HSIL Clearance by complete regression or disappear of the original lesions, with clearance rates calculated per the following formula: Percentage of Participants with No Histologic Evidence of HSIL (%) = Number of Participants Achieving HSIL Clearance / Total number of Participants treated with BD114 ×100%

    Time frame: Week 24, Week 36

Secondary outcomes

  1. Percentage of Participants with No Histologic Evidence of HSIL and No Evidence of HPV-16

    Virological HPV-16 assessment was performed using clinically validated type-specific HPV testing kits, meanwhile colposcopy-guided cervical tissue biopsies are histopathologically evaluated. The calculating formula as follow: Percentage of Participants with No Histologic Evidence of HSIL and No Evidence of HPV-16 = Number of Participants with No Histologic Evidence of HSIL and No Evidence of HPV-16 / Total number of Participants treated with BD114 ×100%

    Time frame: Week 24, Week 36

  2. Percentage of Participants with No Evidence of HPV-16

    Histological samples (cervical exfoliated cells) is detected for HPV-16 by real-time fluorescent quantifying PCR technology. The calculating formula as follow: Percentage of Participants with No Evidence of HPV-16 = Number of Participants with No Evidence of HPV-16 / Total number of Participants treated with BD114 ×100%

    Time frame: Week 24, Week 36

  3. Percentage of Participants with No Evidence of HSIL or LSIL

    Cervical biopsies at Week 36 are performed for histopathological evaluation, no histologically evidence of HSIL or LSIL of histological samples are judged as no histology findings of HSIL or LSIL. The calculating formula as follow: Percentage of Participants with No Evidence of HSIL or LSIL = Number of Participants with No Evidence of HSIL or LSIL / Total number of Participants treated with BD114 ×100%

    Time frame: Week 36

  4. Percentage of Participants with No Evidence of HSIL or LSIL and No Evidence of HPV-16

    Cervical biopsies at Week 36 are performed for histopathological evaluation, no histologically evidence of HSIL or LSIL of histological samples are judged as no histology findings of HSIL or LSIL. Histological samples (cervical exfoliated cells) is detected HPV-16 by real-time fluorescent quantifying PCR technology. Calculation Formula: Percentage of Participants with No Evidence of HSIL or LSIL and No Evidence of HPV-16 = Number of Participants A with No Evidence of HSIL or LSIL and No Evidence of HPV-16 / Total number of Participants treated with BD114 ×100%

    Time frame: Week 36

  5. Changes in Serum Inflammatory Cytokine (IL-1/IL-6/TNF-α/IFN-γ) Levels Relative to Baseline

    Blood samples were collected and analyzed using clinically validated ELISA kits to quantify serum levels of four inflammatory cytokines (IL-1, IL-6, TNF-α, and IFN-γ).

    Time frame: Day0, Day 2, Week 1, Week 2, Week 4, Week 12, Week 24, and Week 36.

  6. Concentrations of Cas9 Protein and gRNA in Peripheral Blood

    The concentration of Cas9 protein are tested by ELISA and gRNA are detected by qPCR in blood.

    Time frame: At Day0, Day 2, Week 1, Week 4, Week 12.

  7. Detection of Anti-p24/Cas9 Protein Antibodies in Peripheral Blood

    The detection of anti-p24/Cas9 protein antibodies in blood are performed at scheduled study visits.

    Time frame: At Day0, Week 2, Week 4, Week 36

  8. Off-Target Analysis

    Off-Target analysis of cervical biopsy samples is conducted by applying DNA deep sequencing or whole genome sequencing (WGS) to assess BD114-related off-target effects based on the sequencing results.

    Time frame: D0, Week 1

07

Study locations

1 site
  • Obstetrics & Gynecology Hospital of Fudan University
    Shanghai, 200090, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Aug 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 12, 2025
StartActual
Sep 15, 2025
Primary completionActual
Aug 21, 2026
CompletionActual
Aug 21, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07170254
Lead sponsor
Shanghai BDgene Co., Ltd.
Collaborators
Obstetrics & Gynecology Hospital of Fudan University
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 15, 2025
Primary completion
Aug 21, 2026
Completion
Aug 21, 2026
Last update
Sep 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion